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Background
The goal of highly active antiretroviral therapy (HAART)
is to suppress HIV RNA to undetectable levels over many
years and is primarily dependent on adherence, which is
aided by using a once daily regimen with good tolerability
and low pill burden. In Study 934 the time to disconti-
nuation for the twice daily regimen of EFV qd + zidovu-
dine/lamivudine bid was significantly shorter than for the
once daily regimen (EFV+FTC+TDF) (p=0.003). Herein
are the 5 year safety and efficacy data for this once daily
regimen.
Methods
160 subjects (89% male, 64% white, mean age 41 yrs) in
Study 934 originally randomized to the once daily regimen
of EFV+FTC+TDF who completed 144 weeks agreed to
switch to the single tablet formulation (EFV/FTC/TDF)
and remain on study for an additional 96 weeks for a total
of 240 weeks.
Results
At baseline (BL), mean HIV RNA= 5.03 log10 c/mL,
mean CD4 count= 243 cells/mm
3, and 88% had sympto-
matic HIV or AIDS. After 240 weeks of follow-up:
87% had HIV RNA <400 c/mL and 84% <50 c/mL
(M=F); mean CD4 cell increase from BL= 346 cells/mm
3.
The mean (range) adherence rate was 97% (83-100%).
Seventeen subjects discontinued EFV/FTC/TDF: with-
drew consent (6); lost to follow-up (5); adverse events (2:
osteoporosis (1) and anal cancer (1)); incarceration (2);
non-adherence (1); and relocated (1). No patient discon-
tinued due to renal adverse events. Mean change from
BL in estimated glomerular filtration rate (e-GFR)
by Cockcroft-Gault was -7 mL/min (Mean BL e-GFR,
129 mL/min).
Conclusions
Through 240 weeks, the once daily HAART regimen of
EFV+FTC+TDF (dosed as single tablet regimen, EFV/
FTC/TDF, from Week 144-240) demonstrated durable
antiretroviral efficacy and immunologic recovery in anti-
retroviral-naïve patients. The decline in e-GFR was mild
and not clinically significant.
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